지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 408 - 412 (5page)
이용수
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.
목차
등록된 정보가 없습니다.
참고문헌 (9)
참고문헌 신청
Ohashi K / 2013 / Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease / J Clin Oncol 31:1070~1080
Yen-Hsiang Huang / 2018 / The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma / Cancer Research and Treatment 50(4):1294~1303
Wang S / 2016 / EGFR C797S mutation mediates resistance to third-generation inhibitors in T790Mpositive non-small cell lung cancer / J Hematol Oncol 9:59
Ercan D / 2015 / EGFR mutations and resistance to irreversible pyrimidinebased EGFR inhibitors / Clin Cancer Res 21:3913~3923
Shin HT / 2017 / Prevalence and detection of low-allele-fraction variants in clinical cancer samples / Nat Commun 8:1377
Yen-Hsiang Huang / 2018 / The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma / Cancer Research and Treatment 50(4):1294~1303
Wang S / 2016 / EGFR C797S mutation mediates resistance to third-generation inhibitors in T790Mpositive non-small cell lung cancer / J Hematol Oncol 9:59
Ercan D / 2015 / EGFR mutations and resistance to irreversible pyrimidinebased EGFR inhibitors / Clin Cancer Res 21:3913~3923
Shin HT / 2017 / Prevalence and detection of low-allele-fraction variants in clinical cancer samples / Nat Commun 8:1377
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer
Cancer Research and Treatment
2022 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .01
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]
Journal of Pharmaceutical Investigation
2019 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
-
EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
Journal of Pathology and Translational Medicine
2021 .01
-
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non?small cell lung carcinoma
Journal of Pathology and Translational Medicine
2021 .01
-
Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing
Yonsei Medical Journal
2018 .01
-
Animal models and therapeutic molecular targets of lung cancer
한국실험동물학회 학술발표대회 논문집
2019 .01
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2017 .01
-
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
Cancer Research and Treatment
2024 .07
-
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment
2023 .04
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0